{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.2","upperLimit":"14.0","value":"3.1"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"32"}],"units":"Participants"}],"description":"Complete and Partial Tumor Response by RECIST 1.1. Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \\>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.","dispersionType":"90% Confidence Interval","groups":[{"description":"Patients receive trebananib IV over 30-60 minutes on days 1, 8, 15, and 21. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.\n\nTrebananib: Given IV","id":"OG000","title":"Treatment (Trebananib)"}],"paramType":"NUMBER","populationDescription":"Eligible and treated patients.","reportingStatus":"POSTED","timeFrame":"Up to 5 years","title":"Objective Tumor Response (Complete or Partial Response)","type":"PRIMARY","unitOfMeasure":"percentage of participants"}